Improving Pneumococcal Polysaccharide Vaccination in Children With Cystic Fibrosis

Adam Van Mason  
*Children's Mercy Hospital, ajvanmason@cmh.edu*

Wendy Estrellado-Cruz  
*Children's Mercy Hospital, wlestrellado@cmh.edu*

Kristi Williams  
*Children's Mercy Hospital, kwilliams@cmh.edu*

Ellen Meier  
*Children's Mercy Hospital, emmeier@cmh.edu*

Elizabeth Elson

*See next page for additional authors*

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/posters

Part of the Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Pediatric Nursing Commons, Pediatrics Commons, Pulmonology Commons, and the Respiratory Tract Diseases Commons

**Recommended Citation**  
Van Mason, Adam; Estrellado-Cruz, Wendy; Williams, Kristi; Meier, Ellen; Elson, Elizabeth; Duehlmeyer, Stephanie; Capel, Paula; Banks, Jessica; and Oermann, Christopher M., "Improving Pneumococcal Polysaccharide Vaccination in Children With Cystic Fibrosis" (2018). *Posters.* 45.  
https://scholarlyexchange.childrensmercy.org/posters/45

This is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Posters by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact library@cmh.edu.
Authors
Adam Van Mason, Wendy Estrellado-Cruz, Kristi Williams, Ellen Meier, Elizabeth Elson, Stephanie Duehlmeyer, Paula Capel, Jessica Banks, and Christopher M. Oermann

This is available at SHARE @ Children's Mercy: https://scholarlyexchange.childrensmercy.org/posters/45
Improving Pneumococcal Polysaccharide Vaccination In Children With Cystic Fibrosis

Cystic fibrosis (CF) is an inherited, lifelong condition resulting in chronic lung disease. Current guidelines recommend administration of pneumococcal polysaccharide vaccine (PPSV23) to high risk patients, including patients with CF, greater than 2 years of age. Search of our electronic medical records indicated that only 7.7% (11/193) of our CF patients >2 years had received PPSV23. None of our CF providers were regularly administering PPSV23 in their CF clinics and few were aware of the recommendation.

The aim of this project was to increase overall PPSV23 vaccination in our CF population from 7.7% to 30% by 9/1/2018.

Methods

- The primary outcome measure was percentage of patients greater than age 2 years who have received PPSV23.
- Secondary measures included overall vaccination rate during the 23 week duration of the project and reasons for a patient not receiving PPSV23.
- Project interventions included: a report of age eligible patients, education of CF providers, education of CF patients/families through a quarterly newsletter, utilization of an immunization algorithm, incorporation of PPSV23 discussion into pre-clinic huddles, and administration of the vaccine during CF clinic. The first 8 weeks served as a pilot period in half of our CF clinics. At week 13 we expanded vaccination to eligible inpatients.

Results

- During the 23 week period, our overall PPSV23 vaccination among age-eligible CF patients increased from 7.7% to 51.8% (100/193).
- The overall vaccination rate during the study period was 52% (85/163).

Conclusions

- Few CF patients seen in our clinic had received PPSV23 vaccination despite it being the standard of care.
- During a 23 week period we increased vaccination of our CF population primarily through education, utilization of an immunization algorithm, incorporation of PPSV23 into pre clinic planning and administration of the vaccine during CF clinic and during inpatient stays.
- Invasive pneumococcal disease may be decreased through increased immunization of high risk patients.